ANIP
ANI Pharmaceuticals, Inc.
ANIP offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY
Eli Lilly and Company
LLY has the edge over ANIP overall, supported by stronger fundamentals and stronger modeled upside.
ANIP Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Unavailable | |
| Strong |
ANIP's profitability and balance sheet are currently healthy, and its revenue is stable. There isn't enough data to rate its cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ANIP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 7.5x | $71.06 | — |
| Current | 14x | $71.06 | — |
| Cheap | 21x | $103 | +45% |
| Fair | 46x | $228 | +221% |
| Expensive | 81x | $406 | +471% |
Historical ranges are pointers, not guarantees.
ANIP has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ANIP Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for ANIP, but weaker profitability.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over ANIP on the outlook, with more favorable profitability expectations.
ANIP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.52 | +91% |
| Q3 2026 | $4.98 | +188% |
| Q2 2026 | $4.60 | +$5.27 |
| Q1 2026 | $3.91 | +$5.08 |
| Q4 2025 | $3.32 | +$4.36 |
| Q3 2025 | $1.73 | +$2.27 |
| Q2 2025 | -$0.67 | -157% |
| Q1 2025 | -$1.17 | -173% |
| Q4 2024 | -$1.04 | -222% |
ANIP earned $4.98 per share over the past year, up 188% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ANIP on earnings, with more consistent year-over-year improvement.
ANIP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2024 | $148.3M | +13% |
| Q2 2024 | $138M | +18% |
| Q1 2024 | $137.4M | +29% |
| Q4 2023 | $131.7M | +40% |
| Q3 2023 | $131.8M | +57% |
| Q2 2023 | $116.5M | +58% |
| Q1 2023 | $106.8M | +66% |
| Q4 2022 | $94.2M | +55% |
LLY has the stronger quarterly revenue trend. Revenue is up 13% for ANIP versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2024 | -14% | -27 points |
| Q2 2024 | 3.7% | -6.9 points |
| Q1 2024 | 15% | +5.5 points |
| Q4 2023 | 5.1% | +3.2 points |
| Q3 2023 | 14% | +20 points |
| Q2 2023 | 11% | +28 points |
| Q1 2023 | 9.3% | +39 points |
| Q4 2022 | 1.9% | +41 points |
ANIP's operating margin was −14% last quarter, down 27 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ANIP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $70.3M | +85% |
| Q2 2026 | $53.6M | -25% |
| Q1 2026 | $52.3M | +61% |
| Q4 2025 | $29.1M | +116% |
| Q3 2025 | $38M | +395% |
| Q2 2025 | $71.8M | +454% |
| Q1 2025 | $32.5M | +138% |
| Q4 2024 | $13.5M | -68% |
ANIP generated $205M in free cash flow over the past year, up 32% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ANIP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.1% | -240K shares |
| 1 year | +2.8% | +582K shares |
| 3 years | +13% | +2.5M shares |
| 5 years | +79% | +9.6M shares |
| Available history | +80% | +9.6M shares |
ANIP has 22M diluted shares, up 2.8% from a year ago, despite $35M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $13.6M |
| Q2 2026 | $813,000 |
| Q1 2026 | $19.8M |
| Q4 2025 | $611,000 |
| Q3 2025 | $1M |
| Q2 2025 | $551,000 |
| Q1 2025 | $10M |
| Q4 2024 | $318,000 |
ANIP spent $35M buying back its own shares over the past year, up 192% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ANIP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ANIP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 1.0x | Very low |
| Q1 2025 | 2.0x | Moderate |
| Q4 2024 | 2.5x | Moderate |
ANIP has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ANIP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.6 | Neutral |
| Stochastic | 17.1 | Oversold |
ANIP's weekly RSI is 44 (neutral) and its Stochastic is 17 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ANIP PE vs Healthcare Sector
| Metric | ANIP | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 45% below |
| PE % | 1 | 29 | 28 pts below |
ANIP has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ANIP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $71.9 | 1.2% below |
| 20 week MA | $75.0 | 5.3% below |
| 50 week MA | $77.5 | 8.3% below |
| 100 week MA | $74.7 | 4.9% below |
| 200 week MA | $65.2 | 8.9% above |
ANIP has fallen below most of its moving averages, though it's still 8.9% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ANIP on trend strength, trading above more of its moving averages.
ANIP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $61.3 | $28.0 | -54% |
| 2021 | $28.0 | $50.9 | +82% |
| 2022 | $50.9 | $39.5 | -22% |
| 2023 | $39.5 | $55.1 | +40% |
| 2024 | $55.1 | $54.4 | -1.3% |
| 2025 | $54.4 | $82.4 | +51% |
| 2026 YTD | $82.4 | $71.1 | -14% |
ANIP has finished lower in three of the last six years. It's down 14% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ANIP on returns for 2026, with the stronger performance.